2024
Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer
Justice A, Tate J, Howland F, Gaziano J, Kelley M, McMahon B, Haiman C, Wadia R, Madduri R, Danciu I, Leppert J, Leapman M, Thurtle D, Gnanapragasam V. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology 2024, 7: 923-932. PMID: 38171965, DOI: 10.1016/j.euo.2023.11.023.Peer-Reviewed Original ResearchVeterans Health AdministrationCharlson Comorbidity IndexNon-prostate cancer mortalityProstate cancer mortalityNonmetastatic prostate cancerComorbidity indexCancer mortalityProvider estimationProstate cancerHealth AdministrationUS Veterans Health AdministrationElectronic health record-based toolsYear of diagnosisRisk of deathObservational cohortMedian ageNonmetastatic cancerPredicting MortalityC-statisticHispanic ethnicityTreatment groupsMortalityCancerNational validationAge
2021
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Alcorn C, Kidwai-Khan F, Skanderson M, Brittain E, King JT, Ho YL, Eden S, Kundu S, Lann MF, Greevy RA, Ho PM, Heidenreich PA, Jacobson DA, Douglas IJ, Tate JP, Evans SJW, Atkins D, Justice AC, Freiberg MS. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. The BMJ 2021, 372: n311. PMID: 33574135, PMCID: PMC7876672, DOI: 10.1136/bmj.n311.Peer-Reviewed Original ResearchConceptsProphylactic anticoagulationDay mortalityEarly initiationTherapeutic anticoagulationCohort studyInpatient mortalityHospital admissionAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCoronavirus disease 2019 (COVID-19) mortalitySyndrome coronavirus 2 infectionCOVID-19History of anticoagulationSerious bleeding eventsCoronavirus 2 infectionHours of admissionObservational cohort studyRisk of deathCoronavirus disease 2019Real-world evidenceBleeding eventsSubcutaneous heparinHospital stayNationwide cohortCumulative incidence
2020
Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma
Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Re V. Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 71-78. PMID: 31575557, PMCID: PMC6980754, DOI: 10.1158/1055-9965.epi-19-0503.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesCarcinoma, HepatocellularFemaleHepatectomyHIV InfectionsHospitals, VeteransHumansImmunologic SurveillanceKaplan-Meier EstimateLiverLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm StagingRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesConceptsBarcelona Clinic Liver Cancer stageHIV statusHepatocellular carcinomaUninfected patientsHIV infectionTumor characteristicsUninfected personsPathology reportsVeterans Aging Cohort StudyLiver tissue samplingCohort of HIVMultivariable Cox regressionAdvanced hepatic fibrosisAging Cohort StudyLiver Cancer stageRisk of deathBackground hepatic parenchymaCohort studyHazard ratioLymphovascular invasionBCLC stageImproved survivalCox regressionHistologic featuresHepatic fibrosis
2018
Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis
Grover S, Desir F, Jing Y, Bhatia RK, Trifiletti DM, Swisher-McClure S, Kobie J, Moore RD, Rabkin CS, Silverberg MJ, Salters K, Mathews WC, Gill MJ, Thorne JE, Castilho J, Kitahata MM, Justice A, Horberg MA, Achenbach CJ, Mayor AM, Althoff KN. Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 421-429. PMID: 30211722, PMCID: PMC6203623, DOI: 10.1097/qai.0000000000001842.Peer-Reviewed Original ResearchConceptsLung cancer diagnosisCancer diagnosisLung cancerCancer stageNorth American AIDS Cohort CollaborationAdjusted mortality rate ratioHodgkin lymphoma diagnosisOnly lung cancerRole of HIVRisk of deathMortality rate ratiosCohort CollaborationImmune dysfunctionCervical cancerImmune suppressionCancer outcomesSignificant immunosuppressionCancer survivalPoor survivalLymphoma diagnosisMortality rateProbability of survivalPWHHigh mortalityCancerMarkers of chronic obstructive pulmonary disease are associated with mortality in people living with HIV
Triplette M, Justice A, Attia EF, Tate J, Brown ST, Goetz MB, Kim JW, Rodriguez-Barradas MC, Hoo GWS, Wongtrakool C, Akgün K, Crothers K. Markers of chronic obstructive pulmonary disease are associated with mortality in people living with HIV. AIDS 2018, 32: 487-493. PMID: 29135579, PMCID: PMC6366454, DOI: 10.1097/qad.0000000000001701.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseRisk of deathStudy participantsVACS IndexPulmonary diseaseComputed tomographyImpact of COPDVeterans Aging Cohort Study (VACS) IndexMultivariable Cox regression modelsBurden of comorbiditiesPredictors of mortalityPulmonary function testingCox regression modelMedian followUninfected subjectsAirflow obstructionCohort studyPulmonary functionPulmonary variablesFunction testingMultivariable modelPLWHCT characteristicsMortality rate
2017
Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study
Brittain EL, Duncan MS, Chang J, Patterson OV, DuVall SL, Brandt CA, So-Armah KA, Goetz M, Akgun K, Crothers K, Zola C, Kim J, Gibert C, Pisani M, Morris A, Hsue P, Tindle HA, Justice A, Freiberg M. Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study. American Journal Of Respiratory And Critical Care Medicine 2017, 197: 923-932. PMID: 29131651, PMCID: PMC6020408, DOI: 10.1164/rccm.201708-1555oc.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyCD4 cell countHIV viral loadAging Cohort StudyUninfected veteransPulmonary pressurePrevalent comorbiditiesCohort studyViral loadHigh prevalenceCell countLow CD4 cell countsHigher HIV viral loadAntiretroviral therapy eraRisk of deathRace/ethnicityPASP valuesTherapy eraAdjusted riskPulmonary hypertensionObservational cohortPrognostic impactPrimary outcomeClinical featuresHIV statusRisk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection
Re V, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiology And Drug Safety 2017, 26: 1172-1181. PMID: 28722244, PMCID: PMC5624832, DOI: 10.1002/pds.4258.Peer-Reviewed Original ResearchConceptsHepatitis C virusHIV/HCV patientsHuman immunodeficiency virusHepatic decompensationAntiretroviral therapyHCV patientsCohort studyHazard ratioHIV/hepatitis C virus (HCV) coinfectionChronic hepatitis C virusHepatitis C virus coinfectionHIV-/HCV-coinfected patientsHIV/HCV coinfectionVeterans Aging Cohort StudyC virus coinfectionChronic hepatic injuryAging Cohort StudyRisk of deathToxic nucleoside analoguesMarginal structural modelsHCV coinfectionLiver decompensationART regimensDecompensation eventsHepatic injury
2016
First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension Among North American HIV-Infected Adults, 2000–2013
Wong C, Gange SJ, Buchacz K, Moore RD, Justice AC, Horberg MA, Gill MJ, Koethe JR, Rebeiro PF, Silverberg MJ, Palella FJ, Patel P, Kitahata MM, Crane HM, Abraham AG, Samji H, Napravnik S, Ahmed T, Thorne JE, Bosch RJ, Mayor AM, Althoff KN, Research and Design F. First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension Among North American HIV-Infected Adults, 2000–2013. Clinical Infectious Diseases 2016, 64: 459-467. PMID: 28172581, PMCID: PMC5850614, DOI: 10.1093/cid/ciw804.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseHuman immunodeficiency virusDiabetes mellitusAntiretroviral therapyCumulative incidenceKidney diseaseNoncommunicable diseasesNorth American AIDS Cohort CollaborationOccurrence of DMType 2 diabetes mellitusRisk of deathDemographic subgroupsNon-black womenCohort CollaborationHIV populationImmunodeficiency virusTreatment optionsHypertensionAge 70Poisson regressionRacial disparitiesDiseaseBlack womenIncidenceCare
2015
Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients
Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal S, Edelman EJ, Gaither J, Gordon AJ, Goulet J, Kerns RD, Moore BA, Tate J, Justice AC, Fiellin DA. Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 223-233. PMID: 26009831, PMCID: PMC4446730, DOI: 10.1097/qai.0000000000000591.Peer-Reviewed Original ResearchConceptsLong-term opioidsMorphine equivalent daily doseOpioid receiptRisk of deathLong-term prescriptionUninfected patientsOpioid dosesAntiretroviral therapyHazard ratioDaily dosePropensity scoreHigher opioid dosesCause mortalityHIV statusAvailable patientsMortality riskOpioidsHIVPatientsProspective analysisMortalityBenzodiazepinesDosesDeathRisk
2014
Observational Research on NCDs in HIV-Positive Populations
Petersen M, Yiannoutsos CT, Justice A, Egger M. Observational Research on NCDs in HIV-Positive Populations. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 67: s8-s16. PMID: 25117964, PMCID: PMC4317266, DOI: 10.1097/qai.0000000000000253.Peer-Reviewed Original ResearchConceptsNCD risk factorsNoncommunicable diseasesRisk factorsKey NCD risk factorsBurden of NCDsCost-effective prevention strategiesPrevention of NCDsEfficient care strategyIncomplete outcome ascertainmentHIV-positive populationModifiable risk factorsBurden of morbidityRisk of deathPopulation-based sampleHealth system levelClinical decision makingWeb of causationNCD comorbidityHIV-negativeHIV infectionMiddle-income countriesRandomized trialsOutcome ascertainmentHigh-income countriesPrevention strategies
2011
The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis
Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J, Collaboration F. The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Medicine 2011, 13: 89-97. PMID: 21819529, PMCID: PMC4539012, DOI: 10.1111/j.1468-1293.2011.00940.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Therapy, CombinationDrug UsersFemaleHIV InfectionsHumansMaleMiddle AgedOdds RatioProportional Hazards ModelsRisk FactorsRNA, ViralSubstance Abuse, IntravenousViral LoadYoung AdultConceptsCombination antiretroviral therapyCD4 cell countBaseline CD4 cell countDisease progressionCell countCART initiationAntiretroviral therapyHigher baseline HIV viral loadLower baseline CD4 cell countBaseline HIV viral loadSpecific causesART Cohort CollaborationLiver-related deathHIV viral loadHIV-positive individualsRisk of deathCause of deathDrug use historyCohort CollaborationCohort studyCumulative incidenceHazard ratioHIV diseaseClinical AIDSPrior diagnosis
2009
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. New England Journal Of Medicine 2009, 360: 1815-1826. PMID: 19339714, PMCID: PMC2854555, DOI: 10.1056/nejmoa0807252.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyRisk of deathAsymptomatic patientsHuman immunodeficiency virus (HIV) infectionCubic millimeterEarly-therapy groupImmunodeficiency virus infectionPrevious antiretroviral therapyCohort of patientsClinical characteristicsHIV infectionRelative riskEarly initiationVirus infectionCD4PatientsMedical careTherapyDeathCalendar yearInfectionRiskCountSurvivalGroup